Sprout Health logo
Provider review · checked 2 October 2026

Sprout Health review

We may earn a commission if you start a program through links on this page. It doesn't change prices or how we sort them. Disclosure

Visit Sprout Health Affiliate link · we may earn a commission
5comparison programs tracked
$99–$249current catalog monthly range
Medication includedpublished offer basis
FDA warningregulatory record reviewed
Published listings

Sprout Health programs and current prices

5 comparison programs and 0 additional listings, checked 2 October 2026.

View full provider profile
Sprout Health programs and published prices
TreatmentCurrent monthly priceFormatVisit
Semaglutide treatmentSemaglutide$149compounded (not FDA-approved)every 4 weeks; $161.86 annualized monthly equivalent (365-day basis)Weekly injectionVisitAffiliate link · we may earn a commission
Tirzepatide treatmentTirzepatide$199compounded (not FDA-approved)every 4 weeks; $216.18 annualized monthly equivalent (365-day basis)Weekly injectionVisitAffiliate link · we may earn a commission
NAD+ injection treatmentNAD+ injection$249compounded (not FDA-approved)a month after a first month at $199InjectionVisitAffiliate link · we may earn a commission
Wegovy treatmentWegovyNot verifiedconfirm published terms before payingWeekly injectionVisitAffiliate link · we may earn a commission
Zepbound treatmentZepboundNot verifiedconfirm published terms before payingWeekly injectionVisitAffiliate link · we may earn a commission

Verdict: easy to compare, hard to recommend without extra checks

Sprout Health has a straightforward appeal: medication-included cash offers across compounded GLP-1, NAD+, and selected branded weight-loss products. That makes the catalog easier to compare than a membership whose medication cost appears later. The service is best considered by a buyer who values one bundled basis and is willing to investigate the public record before paying.

The caution is substantial. FDA issued a warning letter concerning Sprout's promotion of compounded semaglutide and tirzepatide, and BBB currently assigns the business an F rating tied to complaint response. Trustpilot is more favorable but mixed. Those signals do not decide whether one patient will receive appropriate care, yet they make written fulfillment and cancellation confirmation essential.

The catalog supports real like-for-like comparisons

Sprout's published prices include medication. The comparison below shows the official price source and the date checked, and keeps compounded, branded and NAD+ treatments separate rather than treating them as substitutes.

  • Semaglutidecompounded (not FDA-approved)$149 monthly · $99 effective monthly on the 12-month plan
  • Tirzepatidecompounded (not FDA-approved)$199 monthly · $149 effective monthly on the 12-month plan
  • NAD+ injectioncompounded (not FDA-approved)$249 monthly
  • WegovyNo month-to-month price published
  • ZepboundNo month-to-month price published

Compare each row within the same medication and format. Branded cash prices can change independently of a telehealth service, and compounded products are not FDA-approved versions of the brands. Confirm the current checkout, shipment cadence, and any multi-month commitment even when the displayed amount is medication included.

An independent clinician and partner pharmacy sit behind the order

Sprout Health Partners LLC operates the platform. Its terms say an independent licensed healthcare provider reviews the intake and decides whether to issue a prescription. If approved, a partner pharmacy fills the medication unless the patient selects another licensed pharmacy where that option is available.

The public materials do not promise one pharmacy for every medication and state. Ask for the dispensing pharmacy before fulfillment, then verify the label when the package arrives. Sprout is not the manufacturer of every product displayed on its storefront.

Refund eligibility changes at clinical review and pharmacy handoff

Sprout's July 2026 policy separates three stages. A cancellation before clinician review receives the broadest refund treatment. A completed review can introduce a clinical fee, and an order sent to the pharmacy becomes non-refundable. Multi-month plans use a separate calculation for unshipped months.

The policy also requires advance notice before the next billing date. Keep the portal status and written cancellation confirmation because a stopped subscription does not recall a prescription already sent for fulfillment. Report damaged, incorrect, or temperature-concerning shipments within the short period stated by the policy.

The FDA letter is about compounded-drug promotion

FDA's September 2025 warning letter says Sprout's website promoted compounded semaglutide and tirzepatide with claims that made the products misbranded. The letter is a regulatory notice about the cited promotion and the legal status of compounded drugs.

It should not be rewritten as a recall or a laboratory finding. It does establish that readers should reject language implying a compounded product is FDA approved or evaluated like Wegovy or Zepbound. The specific pharmacy, formulation, prescription, and label still need their own verification.

Consumer sources disagree, and that disagreement matters

Trustpilot's Sprout profile shows a mixed but net-positive aggregate, with both recent praise and service complaints. BBB's profile is much more negative and cites unanswered complaints. ConsumerAffairs and BBB complaint pages also contain individual fulfillment and contact reports.

These platforms have different collection and moderation systems, so their scores should not be averaged into a Telehealth Ledger rating. The common decision point is operational: confirm who will prescribe, who will dispense, when the order becomes non-refundable, and how support will document a problem.

Better alternatives exist for lower-friction buyers

A provider with a clean regulatory record and stronger complaint response may be worth a higher price for someone who prioritizes operational reliability. Insurance-focused readers should compare branded access routes rather than paying a cash figure by default. Compounded-drug shoppers should compare the same ingredient and route while checking pharmacy identity.

Sprout's strength is catalog simplicity. Its weakness is the amount of adverse public context a buyer must reconcile. Proceed only when the written order terms, pharmacy assignment, cancellation deadline, and product status are clear.

Availability changes by program, not only by provider

Sprout's terms checked October 2, 2026 exclude Alabama, Arkansas, California, Louisiana, Mississippi, and North Dakota across services, including weight loss and NAD+. Confirm eligibility for the actual state and requested treatment before intake. Licensure, telehealth rules, pharmacy shipping authority, and the clinician's judgment can each narrow availability. Readers should enter their actual state and requested treatment rather than relying on a nationwide marketing impression or another customer's shipment. A no-data state is unresolved, not proof of access or exclusion.

The same separation applies to branded and compounded products. A clinician may decide a treatment is inappropriate, a pharmacy may be unable to dispense in the patient's state, or a branded product may face an insurance or supply constraint even when Sprout lists it. Confirm whether the quoted path is cash pay, whether medication is included, which pharmacy supplies it, and whether a medical decline triggers the policy's pre-fulfillment refund. If Sprout changes the pharmacy or product after the order, request a new written summary before accepting the shipment.

How this review was prepared

We checked Sprout Health’s public pricing and programme pages on 2 October 2026. The review covers published pricing, plan terms, inclusions, and availability. It is not a rating, a clinical assessment, or a guarantee of eligibility or outcomes.

Evidence limits

  • This review summarizes the linked public sources. Telehealth Ledger has not independently verified Sprout's claims about care, pharmacy assignments, fulfillment or the final terms of an individual order.
  • The FDA letter concerns the cited promotional content and is not a recall, batch test, or blanket finding about every current prescription.
  • Consumer-review and BBB records are dated operational signals, not clinical evidence.
  • State eligibility must be checked for the actual treatment during intake; a published program listing does not guarantee that a particular prescription can be filled in the reader's state.